info:eu-repo/semantics/article
Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma
Fecha
2006-12Registro en:
Bravo Roca, María Fernanda; Mauro, Laura Valeria; Morandi, Ana; Bonadeo, Fernando; Vaccaro, Carlos Alberto; et al.; Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma; Veterinary and Human Toxicology; Journal of Surgical Oncology; 93; 12-2006; 151-160
0022-4790
CONICET Digital
CONICET
Autor
Bravo Roca, María Fernanda
Mauro, Laura Valeria
Morandi, Ana
Bonadeo, Fernando
Vaccaro, Carlos Alberto
Quintana, Guillermo Ojea
Specterman, Sergio
Bal, Elisa Dora
Pallotta, María Guadalupe
Puricelli, Lydia Ines
Lastiri, José
Resumen
BACKGROUND AND OBJECTIVES: Therapy of colorectal tumors (CRC) based on histology and clinical factors is insufficient to predict the evolution of each patient. The finding of molecular abnormalities able to differentiate subgroups of patients with bad prognosis will improve our ability to treat them successfully. Our purpose was to analyze retrospectively the prognostic input of E-cadherin, beta-catenin, metalloproteinases (MMPs) (7 and 9), and tissue inhibitors of metalloproteinases (TIMPs) (1 and 2) in patients with a follow-up period of 5 years. METHODS: Antigen expression was analyzed by immunohistochemistry. Prognostic evaluation was performed with the multivariate proportional hazards model. RESULTS: We demonstrated a concomitant loss of E-cadherin and beta-catenin at membranous level and an abnormal accumulation of nuclear beta-catenin. Besides, we found that all MMPs and TIMPs studied were overexpressed in CRC tissue. There was no association between the expression of any of these molecules and the known clinical-pathological parameters employed in CRC pathology. A multivariate analysis demonstrated that the overall survival could be independently predicted by the loss of E-cadherin and the overexpression of TIMP-2. CONCLUSIONS: The expression of E-cadherin and TIMP-2 could be relevant in determining the prognosis of CRC patients and providing a more accurate mechanism for their classification. (c) 2006 Wiley-Liss, Inc.